Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 1/20 | 0.30 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.30 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30606159 | 0.84 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL26598615 | 0.84 | ADORA2A (0.33) | ADORA2AADORA1 | |
| SCHEMBL31436596 | 0.79 | LMNA (0.32) | — | |
| SCHEMBL4536844 | 0.74 | — | — | |
| SCHEMBL31436623 | 0.74 | LMNA (0.33) | — | |
| SCHEMBL26598742 | 0.74 | LMNA (0.33) | — | |
| SCHEMBL1318237 | 0.72 | LMNA (0.37) | S1PR2 | |
| SCHEMBL1578797 | 0.72 | S1PR2 (0.34) | ADORA2AADORA1S1PR2 | |
| SCHEMBL20574876 | 0.70 | SMARCA2 (0.33) | — | |
| SCHEMBL3295991 | 0.69 | RAD51 (0.32) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117069662-A | Synthesis method of 4, 6-dichloro-2- (difluoromethyl) pyrimidine | 峰成医药科技(天津)有限公司 | 2023-11-17 | — | — | CN | claimed |
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | AMGEN INC. (US) | 2026-05-14 | — | — | US | disclosed |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-06 | — | — | US | disclosed |
| US-12459920-B2 | Targeted protein degradation | MONTE ROSA THERAPEUTICS AG (CH) | 2025-11-04 | — | — | US | disclosed |
| US-20250270190-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION | 2025-08-28 | — | — | US | disclosed |
| EP-4598917-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | Amgen Inc. (US) | 2025-08-13 | — | — | EP | disclosed |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | MONTE ROSA THERAPEUTICS AG (CH) | 2025-07-31 | — | — | US | disclosed |
| EP-4585265-A2 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | Takeda Pharmaceutical Company Limited (JP) | 2025-07-16 | — | — | EP | disclosed |
| EP-4547657-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2025-05-07 | — | — | EP | disclosed |
| CN-119585250-A | KIT inhibitors | 蓝图药品公司 | 2025-03-07 | — | — | CN | disclosed |
| CN-117355521-A | Heteroaryl inhibitors of plasma kallikrein | 武田药品工业株式会社 | 2024-01-05 | — | — | CN | disclosed |
| WO-2024006929-A1 | CD73 COMPOUNDS | GILEAD SCIENCES, INC. (US) | 2024-01-04 | — | — | WO | disclosed |
| CN-117069662-A | Synthesis method of 4, 6-dichloro-2- (difluoromethyl) pyrimidine | 峰成医药科技(天津)有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069662-A | Synthesis method of 4, 6-dichloro-2- (difluoromethyl) pyrimidine | 峰成医药科技(天津)有限公司 | 2023-11-17 | — | — | CN | disclosed |
| CN-117069662-A | Synthesis method of 4, 6-dichloro-2- (difluoromethyl) pyrimidine | 峰成医药科技(天津)有限公司 | 2023-11-17 | — | — | CN | disclosed |
| WO-2023205226-A1 | KIT INHIBITORS | BLUEPRINT MEDICINES CORPORATION (US) | 2023-10-26 | — | — | WO | disclosed |
| WO-2023064343-A1 | SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND USES THEREOF | VANQUA BIO, INC. (US) | 2023-04-20 | — | — | WO | disclosed |
| WO-2023025298-A1 | QUINOLINOFURAN DERIVATIVE AND USE THEREOF | 瑞石生物医药有限公司 | 2023-03-02 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
| WO-2022197758-A1 | HETEROARYL INHIBITORS OF PLASMA KALLIKREIN | SHIRE HUMAN GENETIC THERAPIES, INC. (US) | 2022-09-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132143-A1 | HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF | KRAS, NRAS, HRAS | ADORA2A 4714/4885ADORA1 4497/4885S1PR2 2666/4885 |
| US-20250243180-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | ADORA2A 1654/4885ADORA1 3830/4885S1PR2 1373/4885 |
| US-12459920-B2 | Targeted protein degradation | NEK7, NEK1, RIPK1 | ADORA2A 1667/4885ADORA1 3833/4885S1PR2 1395/4885 |
| US-20250270190-A1 | KIT INHIBITORS | KIT, ABL1, APC | ADORA2A 4324/4885ADORA1 3059/4885S1PR2 3773/4885 |
| US-20250340528-A1 | TARGETED PROTEIN DEGRADATION | NEK7, NEK1, RIPK1 | ADORA2A 1654/4885ADORA1 3830/4885S1PR2 1373/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.